期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血清胸苷激酶1在恶性肿瘤诊断和疗效评估中的意义 被引量：7

Significance of detecting serum thymidine kinase 1 in diagnosis and efficacy evaluation for malignant tumors
原文传递
导出
摘要 目的探讨血清胸苷激酶1(STK1)水平变化在恶性肿瘤诊断和疗效评估中的意义。方法收集不同病理类型、病种、临床分期恶性肿瘤患者103例放疗前、中、后的血清样本,采用印迹免疫-增强化学发光法检测STK1水平。取49例健康体检者血清标本作为对照。结果恶性肿瘤患者放疗前STK1水平为(2.21±0.85)pmol/L,显著高于放疗后的(1.59±0.48)pmol/L和对照组的(1.36±0.86)pmol/L(P<0.05)。放疗前STK1阳性率为56.41%,显著高于放疗后的16.90%和对照组的10.20%(P<0.05)。放疗前头颈部恶性肿瘤患者STK1水平为(1.99±0.64)pmol/L,显著低于胸腹部恶性肿瘤的(2.51±1.1)pmol/L(P<0.05)。放疗后部分缓解患者STK1水平为(1.67±0.47)pmol/L,显著高于完全缓解患者的(1.40±0.48)pmol/L(P<0.05)。放疗后,急性皮肤黏膜反应为Ⅱ度及以上组的STK1水平为(1.76±0.37)pmol/L显著高于I度及以下组的(1.50±0.52)pmol/L(P<0.05)。结论 STK1是恶性肿瘤辅助检查的可靠指标,对恶性肿瘤患者的筛检、诊断、治疗效果评估等有重要的参考价值。 Objective To evaluate the significance of detecting serum thymidine kinase 1（STK1） in the diagnosis and efficacy evaluation for malignant tumors. Methods The samples were collected from 103 cases with different kinds of malignant tumors in the different periods of radiotherapy.Serum STK1 was measured by sensitive chemiluminescence dot-blot assay.The results were compared to those in healthy controls（group C）. Results Serum STK1 in patients with malignant tumors before radiotherapy was （2.21±0.85） pmol/L,which was higher than（1.59±0.48） pmol/L after radiotherapy and（1.36±0.86） pmol/L） in group C（P0.05）.The positive rate of STK1 in patients with malignant tumors before radiotherapy was 56.41%,which was higher than 16.90% after radiotherapy and 10.20% in group C（P0.05）.Serum STK1 before radiotherapy in the patients with cephalocervical malignant tumors was（1.99±0.64） pmol/L,which was lower than （2.51±1.10） pmol/L in the patients with abdominal malignant tumors（P0.05）.Serum STK1 before radiotherapy in the patients with partial remissive malignant tumors was （1.67±0.47） pmol/L, which was higher than（1.54±0.47） pmol/L in complete remissive patients（P0.05）.After radiotherapy,serum STK1 in the patients with severe skin and mucosa reaction was（1.76±0.37） pmol/L,which was higher than（1.50±0.52） pmol/L in the patients with mild skin and mucosa reaction（P0.05）. Conclusion Serum STK1 is a reliable marker for screening and evaluating therapeutic efficacy and prognosis in the patients with malignant tumors.
作者 周菊英 姚怡敏 俞志英 徐晓婷 秦颂兵 吴琼 赵奇 许愿
机构地区 苏州大学附属第一医院放疗科
出处 《江苏医药》 CAS CSCD 北大核心 2012年第9期1055-1058,共4页 Jiangsu Medical Journal
关键词 胸苷激酶1 恶性肿瘤 Thymidine kinase 1 Malignant tumor
分类号 R730 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Elsevier SM, Kueherlapati RS, Nichols EA, et al. Assignment of the gene for galactokinase to human chromosome 17 and its regional localisation to band q21-22[J]. Nature, 1974,251 (5476): 633-636.
  • 2Arner ES, Eriksson S. Mannalian deoxyribonucleoside kinases[J]. Phamac Ther, 1995,67(2) : 155-186.
  • 3Fujiwaki R, Hata K, Nakayama K, et al. Thymidine kinase in epithelial overian cancer: relationship with the other pyrimi- dine pathway enzyme[J]. Int J Cancer,2002,99(3):328-335.
  • 4Kauffman MG, Kelly TJ. Cell cycle regulation of thymidine kinase..residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis[J]. Mol Cell Biol, 1991,11(5): 2538-2546.
  • 5Ke PY, Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/ cyclosome-CDHl-mediated pathway[J]. Mol Cell Biol, 2004, 24(2) :514-526.
  • 6Chen ZH, Zhou H, Tian NB, et al. Serological thymidine kinase 1 (STK1) indicates an elevated risk for development of malignant tumours[J]. Anticancer Res, 2008,28 (6B) .. 3897- 3907.
  • 7李小腾,王锋,黄平.直肠癌患者血清胸苷激酶检测的临床意义[J].江苏医药,2009,35(12):1436-1437. 被引量：10
  • 8Li HX,Zhang S,Lei DS, et al. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer[J]. Oncol Rep, 2005,13 ( 1 ) :145-149.
  • 9Zhang J, Quanan J, Shan Z, et al. Thymidine kinase 1 : a prolif- erating marker for prognosis and monitoring the outcome of surgery of primary bladder carcinoma patients[J]. Oncol Rep, 2006,15 (2) : 455-461.
  • 10Galloux H,Javre JI.,Guerin D, et al. Prognostic value of fetal thymidine kinase measurements in breast cancer (fre)[J]. C R Acad Sci Ⅲ ,1988,306(3):89-92.

二级参考文献10

  • 1马小兵,畅继武.免疫组化在前列腺癌病理诊断中作用[J].临床与实验病理学杂志,2007,23(3):354-357. 被引量：4
  • 2Gronowitz JS, Kallander FR, Diderholm H, et al. Application of an in vitro assay serum thymidine kinase: results on viral disease and malignancies in humans[J]. Int J Cancer, 1984,33 (1):5-12.
  • 3Zhang F, Li H, Pendleton AR, et al. Thymidine kinase 1 immunoassay: a potential marker for breast cancer[J]. Cancer Detect Prev,2001,25 (1) :8-15.
  • 4He Q, Zhang P, Zou L, et al. Concentration of thymidine kinase 1 in serum (S-TKI1)is a more sensitive proliferation marker in human solid tumors than its activity[J]. Oncol Rep, 2005,14(4) : 1013-1019.
  • 5Arner ES, Eriksson S. Mammalian deoxynucleoside kinase[J]. Pharmacol Ther, 1995,67(2) : 155-186.
  • 6Gesing A, Modrzejewska H, Karbownik M, et al. Thymidine kinase and adenosine kinase activities in homogenates of thyroid lobes in hemithyroidectomized rats; effects of melatonin in vitro[J]. Neuro Endocrinol Lett,2000,21 (6):453-459.
  • 7Demeter A,Abonyi M,Look KY,et al. Differences in thermostability of thymidine kinase isoenzyrnes in normal ovary and ovarian carcinoma[J]. Anticaneer Res, 2001, 21 (1A) : 353- 358.
  • 8Li HX,Lei DS,Wang XQ,et al. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer[J]. Oncol Rep,2005,13(1) : 145-149.
  • 9Zhang J, J ia Q, Zou S, et al. Thymidine kinase 1:a p roliferation marker for determining prognosis and monitoring the surgical out come of primary bladder carcinoma patients[J]. Oncol Rep, 2006,15 (2) : 455-461.
  • 10郭林,卢仁泉.胃癌患者血清胸苷激酶检测的临床意义[J].检验医学,2008,23(3):271-273. 被引量：25

共引文献9

同被引文献64

  • 1曾智杰,欧阳文婷,孙艳虹,蔡小华.胸苷激酶1在白血病患者化疗过程中的临床意义探讨[J].分子诊断与治疗杂志,2009,1(1):28-30. 被引量：12
  • 2丛玉隆.临床实验室分析前质量管理及对策[J].中华检验医学杂志,2004,27(8):483-487. 被引量：425
  • 3张剑,王京华,刘娟,陈曦.常见血液病患者乳酸脱氢酶测定的临床意义[J].哈尔滨医科大学学报,2006,40(6):504-505. 被引量：11
  • 4Zhang F, Li H, Pendleton AR, et al. Thymidine kinase 1 immunoa say: a potential marker for breast cancer. Cancer Detect Pre 2007,25:8-15.
  • 5He Q, Zou L, Zhang PA, et al. The clinical significance of thymidine kinasel measurement in serum of breast cancer patients using anti- TK1 antibody. Int J Biol Markers, 2000,15 : 139-146.
  • 6Broet P, Romain S, Daver A, et al. Thymidine Kinase as a prolifera- tive marker: clinical relevance in 1692 primary breast cancer patients. J Clin Oncol, 2001,19 : 2778-2787.
  • 7Gilles SI, Romain S, Casellas P, et al. Mutation analysis in the coding sequence of thymidine kinase 1 in breast and colorectal cancer. Int J Biol Markers, 2008,18 : 1-6.
  • 8Gasparri F, Wang N, Skog S, et al. Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site specific antibodies and Arrayscan assays[J]. J Eur Cell Biol, 2009, 88(12) : 779-785.
  • 9Xu XH,Zhang YM,Shu XH,et aL Serum thymidine kinase 1 reflects the progression of premalignant and malignant tumom during therapy[J]. Mol Med Rep, 2008,1 (5) : 705-711.
  • 10Chen HZ,Zhou H,Li S,et al. Serological thymidine Kinase I(STK1) indicates an elevated risk for development of malignant tumours [J]. Anti Caneer Res, 2008,28(18) : 3897-3907.

引证文献7

二级引证文献17

江苏医药
2012年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部